Chu Dijon Bourogne
Dijon, 21000, France
Location status: Recruiting
Recruiting
NCT Number: NCT05635812
Brain and Eye Markers of Facial Expression Recognition and Disorders Associated with Autistic Symptoms
In everyday life, it is necessary to adjust one's behavior and reactions in order to interact and communicate with others in an appropriate manner. This adaptation is done by taking into account the emotions of the people with whom we interact. This reading of emotions is done by using visible clues on the face, in particular by observing the eye area of the interlocutor.
The aim of the study is to investigate how processes such as attention or memory influence emotion recognition, as well as (i) their alteration in the disease, and (ii) their link with the emergence of autistic and/or psychotic symptoms. We also want to study the implementation of compensatory strategies (used to compensate for difficulties in recognizing or perceiving emotions) and the link between the correct use of these strategies and the emergence of autistic and/or psychotic symptoms.
The present project plans to include a total of 120 participants: 30 participants with ASD, 30 patients with a particular genetic deletion 22q11.2 and 60 control participants.
After the inclusion visit, participation in the study will be divided into two half-days in order to perform a neuropsychological assessment, an EEG study and an oculometry study.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
7 year–50 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Person, and if necessary his or her legal representative, who has given his or her non-objection
- Person whose mother tongue is French.
- Person aged between 7 and 50 years old.
- Person diagnosed with ASD according to DSM-5 criteria, person with a genetic syndrome diagnosed by FISH or CGH array (22q11 deletion), person with typical development matched in age and gender.
- Psychotropic treatment unchanged for one month and stable symptomatology.
Exclusion criteria
- Recent addiction according to DSM-5 criteria, excluding tobacco.
- Pregnant women.
- Uncorrected visual acuity disorder.
- Use of somatic or psychic medication that may alter brain/psychic functioning (e.g. corticosteroids).
- Neurological disorder of vascular/infectious or neurodegenerative origin.
Treatment and study plan
Neuropsychological assessment
Otherneuropsychological assessment and clinical scales duration: 3 hours
EEG experimentation
Otherduration: 1 hour
Oculometry experimentation
Otherduration: 30 minutes
Primary outcomes
-
Electrical brain activity in response to visual stimulation measured by electroencephalography
Time frame: at baseline
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
Centre Hospitalier Universitaire Dijon
Other
Registry information
Acronym: MARQUEURS
Important dates
- Study start
- 2023
- Primary completion
- 2026
- Study completion
- 2026
- First posted
- Dec 2, 2022
- Registry last updated
- Oct 4, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.